Refanezumab
Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG) . Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke[1][2].
Product Specifications
CAS Number
1233953-61-1
Product Name Alternative
GSK249320
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/refanezumab.html
Purity
99.9
Solubility
H2O
Smiles
[Refanezumab]
Molecular Weight
(148.28 kDa)
References & Citations
[1]Diana Cash, et al. GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. J Neurol Exp Neurosci. 2016;2 (2) :28-33. Epub 2016 Nov 21.|[2]B Abila, et al. First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93 (2) :163-9.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
253972 50 µL
CD21 (C3DR, CD21, Complement C3d Receptor, Complement Component (3d/Epstein Barr virus) Receptor 2, Complement Receptor Type 2, CR2, EBV Receptor, Epstein-Barr virus Receptor, SLEB9) (FITC) discontinued
Sign In for Pricing
View Details 
PX-TA1778-01 50 µg
Livmoniplimab Biosimilar - Anti-TGFB1 & LRRC32 mAb - Research Grade
Sign In for Pricing
View Details